NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»17/03/2010 [Company watch]
Novartis China: Spectacular Climb in 2009

Novartis AG , the Swiss multinational pharma, said revenues in China grew 36% last year

by: ChinaBio Today Novartis AG , the Swiss multinational pharma, said revenues in China grew 36% last year, far better than the companys overall 11% rise in sales. In 2009, Novartis China was helped by supplying 100 million doses of the companys A[H1N1] pandemic vaccine to China. Novartis China markets pharmaceuticals, vaccines, and diagnostics. China is currently one of Novartis top ten markets, though it is expected to become the companys second biggest market after the United States in five years, according to Dr. Emmanuel Puginier, chairman of Greater China at Novartis Pharmaceuticals Division. By the end of 2009, Novartis had invested $590 million in China. In the next five years, it will add another $1 billion as it builds China’s largest pharmaceutical R&D center in Shanghai.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.